Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Organon & Co - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
OGN
New York
2834
https://www.organon.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Organon & Co
Earnings Preview: Organon (OGN) Q1 Earnings Expected to Decline
- Apr 25th, 2024 2:01 pm
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
- Apr 8th, 2024 10:15 am
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
- Apr 8th, 2024 10:00 am
On International Women's Day, Organon Canada is encouraging businesses to Invest in HER and help address gender inequities through women's health
- Mar 8th, 2024 2:01 pm
Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary
- Feb 20th, 2024 1:00 pm
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023
- Feb 15th, 2024 12:30 pm
Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024
- Feb 1st, 2024 12:30 pm
Organon’s XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older
- Jan 10th, 2024 12:33 pm
Organon affirms 2023 revenue and Adjusted EBITDA guidance and provides 2024 outlook
- Jan 8th, 2024 12:30 pm
Organon To Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Dec 21st, 2023 12:30 pm
Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines
- Dec 18th, 2023 12:30 pm
Organon To Present at the Piper Sandler 35th Annual Healthcare Conference
- Nov 21st, 2023 12:30 pm
Samsung Bioepis & Organon Announce FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (adalimumab-bwwd), a Biosimilar to Humira®
- Nov 7th, 2023 9:15 pm
Organon Reports Results for the Third Quarter Ended September 30, 2023
- Nov 2nd, 2023 11:30 am
Organon and Sempre Health Announce Collaboration on New Service to Help Eligible Patients Save Money and Stay on Their Medication as Prescribed
- Nov 1st, 2023 11:30 am
Organon Canada Announces Availability of a High-Concentration, Citrate-Free Formulation of HADLIMA®, a Biosimilar to HUMIRA*
- Oct 26th, 2023 11:00 am
Organon To Report Third Quarter Results and Host Conference Call on November 2, 2023
- Oct 19th, 2023 11:30 am
Lululemon Athletica & Hubbell Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
- Oct 13th, 2023 10:02 pm
Goldman Sachs Says These 2 Stocks Could Double Your Money — Here’s Why They Could Jump
- Oct 6th, 2023 7:07 pm
Organon Recognized on Fortune’s 2023 Change the World List for Leadership in Expanding Access to Contraceptive Choice
- Sep 27th, 2023 11:30 am
Scroll